Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150967 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
A Phase 2 study, sponsored by QED Therapeutics, a BridgeBio company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT02150967: Clinical Trial Phase 2 study, sponsored by QED Therapeutics, a BridgeBio company.
NCT02150967 is a Phase 2 study that was terminated before completion, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 143 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02150967, a Phase 2 study, was terminated before completion, sponsored by QED Therapeutics, a BridgeBio company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
Primary Outcome
ORR is defined as the percentage (%) of subjects with a best overall response of Complete Response (CR) or Partial Response (PR), as per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR
Interventions
- DRUG BGJ398 (infigratinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2014-07-23 |
| Est. Completion | 2022-02-07 |
| Phase | Phase 2 |
Why NCT02150967 stopped before completion
NCT02150967 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which BGJ398 (infigratinib) is the first listed.
NCT02150967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02150967 about?
NCT02150967 is a clinical study titled "A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma". This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
What is the current status of trial NCT02150967?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2014-07-23. Estimated completion is 2022-02-07.
What interventions are being tested in trial NCT02150967?
The interventions under investigation include: BGJ398 (infigratinib) (DRUG).
Who is sponsoring clinical trial NCT02150967?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02150967's enrollment target sits among peer trials
143 507th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI